Zimmer Biomet Recasts 2025 Financials for Segment Changes
Zimmer Biomet Holdings, Inc. is recasting certain financial information and related disclosures from its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This action is taken due to changes in the composition of its operating segments, which resulted from shifts in senior leader responsibilities and how operating profit information is presented. Specifically, the Foot and Ankle business in Europe, Middle East, Africa, and Asia Pacific, along with certain product category expenses like centralized research and development and global marketing, are now included in the Americas operating segment. The recast impacts the Management’s Discussion and Analysis and Financial Statements sections of the 2025 Form 10-K.
Key Highlights
- Zimmer Biomet is recasting financial information from its 2025 Form 10-K.
- Recast due to changes in operating segment composition.
- Changes driven by shifts in senior leader responsibilities.
- Foot and Ankle business (EMEA, APAC) now included in Americas segment.
- Centralized R&D and global marketing expenses now in Americas segment.
- Recast affects Management’s Discussion and Analysis and Financial Statements.
- No other revisions made to the 2025 Form 10-K.
Price Impact
More from ZBH